Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

CytoMed Therapeutics and Hangzhou CNK Therapeutics Enter Memorandum of Understanding (MOU)

Wednesday, August 16, 2023

CytoMed Therapeutics has announced its recent collaboration with Hangzhou CNK Therapeutics, marked by the signing of a Memorandum of Understanding (MOU). 

This collaboration is aimed at bolstering the in vivo longevity of allogeneic CAR γδ T cells. Notably, this MOU represents the first of multiple cooperative endeavours in North Asia.  

With this agreement, CytoMed gains access to CNK's PiggyBac technology, a non-viral gene editing method, enabling the permanent integration of the Chimeric Antigen Receptor (CAR) gene into its gamma delta (γδ) T cells.

The MOU comes with a one-year duration, subject to renewal, and contingent upon a definitive agreement and customary closing conditions. Additionally, the potential for a joint venture to conduct clinical trials in China remains on the horizon.

These strategic collaborations significantly enhance CytoMed's technological prowess, propelling closer to the aspiration of advancing cost-effective, "off-the-shelf" allogeneic cellular immunotherapies to address a wide range of cancer types.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024